{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T14:47:03Z","timestamp":1785422823013,"version":"3.56.0"},"reference-count":48,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Department of Urology, Wake Forest Baptist Medical Center"},{"id":[{"id":"https:\/\/ror.org\/04v8djg66","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Bladder cancer is the fifth most common cancer in the United States, causing approximately 17,000 deaths annually. Due to its vast genetic and molecular heterogeneity, presentation, prognosis, and therapeutic response vary greatly between individuals. To improve patient outcomes, there is a need for better drug-screening platforms. The genetic heterogeneity of bladder cancer often leads to chemotherapy resistance or low response rates. Moreover, chemotherapies are often contraindicated in patients with select comorbidities. Organoids offer a better option to replicate the tumor microenvironment than traditional 2D cell cultures, improving drug development and personalized therapy. In this study, we bioprinted gelatin-methacrylol (GelMA)-based organoids containing bladder cancer cell lines of different grades to model muscle-invasive bladder cancer. In the organoids, we observed distinct grade-dependent tumor proliferation and progression dynamics. Treatment with standard-of-care chemotherapies revealed a grade-dependent tumor response consistent with in vivo patient data, highlighting the suitability of these organoids for rapid, reliable drug testing. Lastly, we used the organoids to test LCI139, a novel small-molecule inhibitor of PI3K, CDK4\/6, and CDK9 designed for the treatment of epithelial cancers, underscoring the potential of our model to evaluate the efficacy of newly developed drugs. The ability to quickly biofabricate reproducible bladder cancer organoids that are adaptable to different tumor grades represents a novel strategy to create an in vitro platform with strong potential to predict treatment outcomes of bladder cancer patients.<\/jats:p>","DOI":"10.3390\/ijms27136082","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T13:19:31Z","timestamp":1783430371000},"page":"6082","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bioprinted Bladder Cancer Organoids Model System for Prediction of Chemotherapy Response and Drug Screening"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2334-8926","authenticated-orcid":false,"given":"Randall G.","family":"Bissette","sequence":"first","affiliation":[{"name":"Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston-Salem, NC 27101, USA"},{"name":"Department of Urology, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Congress","sequence":"additional","affiliation":[{"name":"Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston-Salem, NC 27101, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Nomdedeu-Sancho","sequence":"additional","affiliation":[{"name":"Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston-Salem, NC 27101, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6917-3487","authenticated-orcid":false,"given":"Nadeem","family":"Wajih","sequence":"additional","affiliation":[{"name":"Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston-Salem, NC 27101, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishnaiah","family":"Maddeboina","sequence":"additional","affiliation":[{"name":"Atrium Health Levine Cancer Center, Charlotte, NC 28204, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shay","family":"Soker","sequence":"additional","affiliation":[{"name":"Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston-Salem, NC 27101, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"ref_1","unstructured":"(2026, May 05). Cancer Stat Facts: Bladder Cancer, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/urinb.html."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e076743","DOI":"10.1136\/bmj-2023-076743","article-title":"Advances in diagnosis and treatment of bladder cancer","volume":"384","author":"Cookson","year":"2024","journal-title":"BMJ"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Huang, H., Hao, H., Du, J., Pang, L., Ma, Q., Li, H., and Jin, L. (2025). A nomogram for predicting overall survival in patients with muscle-invasive bladder cancer undergoing radical cystectomy: A retrospective cohort study. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1597107"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/JU.0000000000003846","article-title":"Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA\/SUO Guideline: 2024 Amendment","volume":"211","author":"Holzbeierlein","year":"2024","journal-title":"J. Urol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/JU.0000000000003981","article-title":"Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA\/ASCO\/SUO Guideline (2017; Amended 2020, 2024)","volume":"212","author":"Holzbeierlein","year":"2024","journal-title":"J. Urol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","article-title":"European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines","volume":"85","author":"Cathomas","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Inamura, K. (2018). Bladder Cancer: New Insights into Its Molecular Pathology. Cancers, 10.","DOI":"10.3390\/cancers10040100"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"The Cancer Genome Atlas Research Network (2014). Comprehensive molecular characterization of urothelial bladder carcinoma. Nature, 507, 315\u2013322.","DOI":"10.1038\/nature12965"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.1158\/1078-0432.CCR-10-0606","article-title":"Prediction of stage, grade, and survival in bladder cancer using genome-wide expression data: A validation study","volume":"16","author":"Lauss","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"107302","DOI":"10.1016\/j.phrs.2024.107302","article-title":"Relationship between clonal evolution and drug resistance in bladder cancer: A genomic research review","volume":"206","author":"Tuo","year":"2024","journal-title":"Pharmacol. Res."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Abugomaa, A., Elbadawy, M., Yamawaki, H., Usui, T., and Sasaki, K. (2020). Emerging Roles of Cancer Stem Cells in Bladder Cancer Progression, Tumorigenesis, and Resistance to Chemotherapy: A Potential Therapeutic Target for Bladder Cancer. Cells, 9.","DOI":"10.3390\/cells9010235"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1038\/s41467-017-02320-7","article-title":"Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer","volume":"8","author":"Liu","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1038\/s41467-023-37696-2","article-title":"Bladder cancer organoids as a functional system to model different disease stages and therapy response","volume":"14","author":"Minoli","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1245\/s10434-019-08143-8","article-title":"Model of Patient-Specific Immune-Enhanced Organoids for Immunotherapy Screening: Feasibility Study","volume":"27","author":"Votanopoulos","year":"2020","journal-title":"Ann. Surg. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/bs.pmbts.2022.03.004","article-title":"Patient-derived organoids as a model for tumor research","volume":"189","author":"Wang","year":"2022","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Sun, M., Sun, X., Wang, Z., Guo, S., Yu, G., and Yang, H. (2018). Synthesis and Properties of Gelatin Methacryloyl (GelMA) Hydrogels and Their Recent Applications in Load-Bearing Tissue. Polymers, 10.","DOI":"10.3390\/polym10111290"},{"key":"ref_19","first-page":"47","article-title":"Biomedical applications of gelatin methacryloyl hydrogels","volume":"2","author":"Piao","year":"2021","journal-title":"Eng. Regen."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"115359","DOI":"10.1016\/j.celrep.2025.115359","article-title":"Adhesion strength of tumor cells predicts metastatic disease in vivo","volume":"44","author":"Kane","year":"2025","journal-title":"Cell Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1158\/1538-7445.AM2024-1816","article-title":"In silico design of novel multitarget small molecule inhibitor LCI139 for the treatment of PTEN-mutant endometrial carcinoma","volume":"84","author":"Mujumdar","year":"2024","journal-title":"Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.1182\/blood-2023-190023","article-title":"The Novel CDK9\/CDK4\/6\/PI3K Triple Inhibitor LCI139 for the Treatment of MYC-Driven Mantle Cell Lymphoma","volume":"142","author":"Pal","year":"2023","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Borowczak, J., Szczerbowski, K., Maniewski, M., Zdrenka, M., S\u0142upski, P., Antosik, P., Ko\u0142odziejska, S., Sekielska-Domanowska, M., Dubiel, M., and Bodnar, M. (2022). The Prognostic Role of CDK9 in Bladder Cancer. Cancers, 14.","DOI":"10.3390\/cancers14061492"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1007\/s00262-020-02609-5","article-title":"Combination of cyclin-dependent kinase and immune checkpoint inhibitors for the treatment of bladder cancer","volume":"69","author":"Long","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"6580","DOI":"10.1158\/1078-0432.CCR-17-0033","article-title":"The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer","volume":"23","author":"Zeng","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.juro.2017.04.086","article-title":"Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA\/ASCO\/ASTRO\/SUO Guideline","volume":"198","author":"Chang","year":"2017","journal-title":"J. Urol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2414558","DOI":"10.1002\/advs.202414558","article-title":"Patient-Derived Bladder Cancer Organoids as a Valuable Tool for Understanding Tumor Biology and Developing Personalized Treatment","volume":"12","author":"Zhao","year":"2025","journal-title":"Adv. Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.cell.2018.03.017","article-title":"Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer","volume":"173","author":"Lee","year":"2018","journal-title":"Cell"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Berndt-Paetz, M., Han, S., Weimann, A., Reinhold, A., N\u00fcrnberger, S., and Neuhaus, J. (2023). Cell Line-Based Human Bladder Organoids with Bladder-like Self-Organization-A New Standardized Approach in Bladder Cancer Research. Biomedicines, 11.","DOI":"10.3390\/biomedicines11112958"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41578-020-0199-8","article-title":"Synthetic alternatives to Matrigel","volume":"5","author":"Aisenbrey","year":"2020","journal-title":"Nat. Rev. Mater."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"102295","DOI":"10.1016\/j.scr.2021.102295","article-title":"Matrigel is required for efficient differentiation of isolated, stem cell-derived otic vesicles into inner ear organoids","volume":"53","author":"Hocevar","year":"2021","journal-title":"Stem Cell Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.semcancer.2005.05.004","article-title":"Matrigel: Basement membrane matrix with biological activity","volume":"15","author":"Kleinman","year":"2005","journal-title":"Semin. Cancer Biol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0014-4827(92)90397-Q","article-title":"Identification of multiple active growth factors in basement membrane Matrigel suggests caution in interpretation of cellular activity related to extracellular matrix components","volume":"202","author":"Vukicevic","year":"1992","journal-title":"Exp. Cell Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s10616-014-9727-y","article-title":"Proteome array identification of bioactive soluble proteins\/peptides in Matrigel: Relevance to stem cell responses","volume":"67","author":"Talbot","year":"2015","journal-title":"Cytotechnology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"6863","DOI":"10.1038\/s41598-019-42186-x","article-title":"Gelatin methacryloyl and its hydrogels with an exceptional degree of controllability and batch-to-batch consistency","volume":"9","author":"Zhu","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Savsani, K., Aitchison, A.H., Allen, N.B., Adams, E.A., and Adams, S.B. (2025). The Use of Gelatin Methacrylate (GelMA) in Cartilage Tissue Engineering: A Comprehensive Review. Bioengineering, 12.","DOI":"10.3390\/bioengineering12070700"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e20220038","DOI":"10.1002\/SMMD.20220038","article-title":"Basic fibroblast growth factor-loaded methacrylate gelatin hydrogel microspheres for spinal nerve regeneration","volume":"2","author":"Chen","year":"2023","journal-title":"Smart Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/jbm.a.36226","article-title":"Gelatin methacrylate scaffold for bone tissue engineering: The influence of polymer concentration","volume":"106","author":"Celikkin","year":"2018","journal-title":"J. Biomed. Mater. Res. A"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1007\/s10439-019-02269-2","article-title":"Development of a Colorectal Cancer 3D Micro-tumor Construct Platform From Cell Lines and Patient Tumor Biospecimens for Standard-of-Care and Experimental Drug Screening","volume":"48","author":"Forsythe","year":"2020","journal-title":"Ann. Biomed. Eng."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e19802","DOI":"10.1016\/j.heliyon.2023.e19802","article-title":"The role of cancer-associated fibroblasts in bladder cancer progression","volume":"9","author":"Huang","year":"2023","journal-title":"Heliyon"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Hol\u00ed\u010dkov\u00e1, A., Ro\u0161ka, J., \u00d3r\u00e1sov\u00e1, E., Bruderov\u00e1, V., Palacka, P., Jurkovi\u010dov\u00e1, D., and Chovanec, M. (2022). Response of the Urothelial Carcinoma Cell Lines to Cisplatin. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232012488"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/j.1464-410X.2008.08098.x","article-title":"Chemosensitization of gemcitabine-resistant human bladder cancer cell line both in vitro and in vivo using antisense oligonucleotide targeting the anti-apoptotic gene, clusterin","volume":"103","author":"Muramaki","year":"2009","journal-title":"BJU Int."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41598-021-04035-8","article-title":"In vitro assessment of intra-operative and post-operative environment in reducing bladder cancer recurrence","volume":"12","author":"Tse","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e70584","DOI":"10.1002\/jbt.70584","article-title":"Exploring the Effectiveness of Sitagliptin to Enhance Cisplatin Chemosensitivity in HTB-9 Bladder Cancer Cells","volume":"39","author":"Mohtadi","year":"2025","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"ref_45","first-page":"3757","article-title":"5-azacytidine reverses drug resistance in bladder cancer cells","volume":"31","author":"Ramachandran","year":"2011","journal-title":"Anticancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13036-025-00535-7","article-title":"Enhancing the therapeutic efficacy of gemcitabine in bladder cancer through TGF-\u03b21 inhibition and pluronic F-127-based microsphere delivery","volume":"19","author":"Xiong","year":"2025","journal-title":"J. Biol. Eng."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/978-3-030-59038-3_17","article-title":"The Tumor Microenvironment of Bladder Cancer","volume":"Volume 1296","author":"Hatogai","year":"2020","journal-title":"Tumor Microenvironments in Organs"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"19563","DOI":"10.1038\/s41598-023-44028-3","article-title":"Tumor microenvironment heterogeneity in bladder cancer identifies biologically distinct subtypes predicting prognosis and anti-PD-L1 responses","volume":"13","author":"Li","year":"2023","journal-title":"Sci. Rep."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/13\/6082\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T12:54:49Z","timestamp":1783515289000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/13\/6082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":48,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["ijms27136082"],"URL":"https:\/\/doi.org\/10.3390\/ijms27136082","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]}}}